In their news article in Laborjournal, the Dresden-based start-up Seamless Therapeutics reflects on programmable recombinases that operate independently of the cell’s own DNA repair system and could thus in future make it possible to cure the disease haemophilia A, for which currently merely the symptoms are treated.
Frank Buchholz is a founding member of the start-up and head of the Medical Systems Biology research group at the Faculty of Medicine Carl Gustav Carus of TU Dresden, which developed the recombinase technology.